+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cryptococcosis Market - Global Forecast 2026-2032- Product Image
Cryptococcosis Market - Global Forecast 2026-2032- Product Image
Sale

Cryptococcosis Market - Global Forecast 2026-2032

  • Report

  • 182 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 6083757
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Cryptococcosis Market is projected to reach USD 7.18 Billion in 2026. It is expected to continue growing at a CAGR of 4.72%, reaching USD 9.49 Billion by 2032.

Cryptococcosis is a serious invasive fungal disease caused primarily by Cryptococcus neoformans and Cryptococcus gattii, with cryptococcal meningitis representing the highest-mortality presentation. The disease burden is concentrated among people with advanced HIV disease, transplant recipients, patients receiving immunosuppressive therapies, malignancy patients, and other immunocompromised populations.

WHO and CDC guidance position cryptococcal antigen (CrAg) screening, rapid diagnosis, and timely antifungal treatment as central to reducing mortality. For the cryptococcosis market, growth is shaped by demand for CrAg lateral flow assays, cerebrospinal fluid diagnostics, fungal culture, amphotericin B formulations, flucytosine access, fluconazole maintenance therapy, and integrated HIV care pathways.

Transformative Shifts in the Cryptococcosis Landscape

The cryptococcosis landscape is shifting from reactive hospital-based treatment toward earlier detection in high-risk populations. WHO recommends CrAg screening for people with advanced HIV disease, particularly those with low CD4 counts, because antigenemia can precede meningitis and create an opportunity for pre-emptive antifungal therapy.

Treatment standards are also evolving. WHO guidance supports optimized induction regimens, including liposomal amphotericin B-based approaches where available, alongside flucytosine and fluconazole. Market transformation is therefore tied to affordability, supply reliability, clinical training, lumbar puncture capacity, therapeutic monitoring, and diagnostic decentralization in countries with the highest HIV-associated disease burden.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence cryptococcosis care through risk stratification, clinical decision support, laboratory workflow automation, and surveillance analytics. AI models can help identify patients with advanced HIV disease who are overdue for CD4 testing, CrAg screening, lumbar puncture evaluation, or follow-up after antifungal initiation.

The near-term value of AI is operational rather than substitutive. Algorithms can flag abnormal laboratory patterns, support antifungal stewardship, analyze imaging when pulmonary or central nervous system disease is suspected, and improve outbreak or cluster detection. However, AI adoption must be validated locally and integrated with clinician-led diagnosis, confirmatory testing, ethics safeguards, data quality controls, and pharmacovigilance.

Key Regional Insights

Asia-Pacific contains large immunocompromised populations and diverse healthcare access levels, making cryptococcosis management highly variable. China, India, Japan, South Korea, and Australia combine advanced tertiary care capacity with persistent gaps in early fungal diagnosis, while ASEAN countries face stronger pressure to expand CrAg screening, laboratory referral systems, and affordable antifungal availability. India and China are particularly important because large HIV, oncology, transplant, and chronic disease populations increase the need for scalable cryptococcosis diagnostics and treatment pathways.

North America benefits from established infectious disease networks, transplant programs, fungal reference laboratories, and access to advanced antifungal formulations, with demand concentrated in HIV care, oncology, critical care, and post-transplant management. Europe shows similar strengths through guideline-based care, antifungal stewardship, and structured hospital diagnostics, although country-level differences remain in reimbursement and access to specialized mycology testing.

Latin America demonstrates rising awareness of invasive fungal disease but continues to face uneven access to rapid diagnostics, flucytosine, and advanced amphotericin B formulations across public healthcare systems. The Middle East shows demand linked to tertiary hospitals, transplant services, oncology care, and expatriate populations, with procurement often focused on reliable diagnostic quality and specialist hospital treatment. Africa remains especially important because HIV-associated cryptococcal meningitis continues to drive preventable mortality where CrAg screening, lumbar puncture access, flucytosine, amphotericin B supply, and follow-up systems are inconsistent.

Key Group Insights

ASEAN markets are shaped by HIV program integration, variable public laboratory capacity, and opportunities to deploy point-of-care CrAg testing closer to community and district-level care. Countries across the bloc face a practical need to link screening with confirmatory assessment, antifungal procurement, and clinician training so that cryptococcal antigen positivity translates into timely pre-emptive therapy or meningitis management.

The GCC shows demand linked to tertiary hospitals, transplant services, oncology care, and care for expatriate populations, with procurement often focused on high-quality diagnostics and advanced antifungal therapies. The European Union and G7 countries prioritize guideline-based care, reimbursement, antifungal stewardship, surveillance of invasive fungal infections, and resilient hospital supply chains that support access to CrAg testing, lumbar puncture-based diagnosis, and induction therapy.

BRICS nations represent substantial strategic relevance due to large populations, expanding healthcare systems, rising transplant and oncology care, and continuing HIV-associated cryptococcosis needs in several member countries. NATO countries overlap with many high-income markets where preparedness, military health systems, cross-border procurement coordination, and secure medical supply chains influence diagnostic and antifungal availability for severe fungal infections.

Key Country Insights

The United States and Canada have strong diagnostic and specialist care capacity, with demand concentrated in HIV care, transplant medicine, oncology, rheumatology-associated immunosuppression, and critical care. Mexico and Brazil face dual needs for advanced hospital management and broader access to rapid diagnostics, particularly where public health systems must connect HIV programs, referral hospitals, and antifungal supply chains to reduce cryptococcal meningitis mortality.

The United Kingdom, Germany, France, Italy, and Spain benefit from structured infectious disease services, hospital mycology expertise, reimbursement frameworks, and antifungal stewardship programs that support appropriate testing and treatment. Russia presents demand across HIV care and hospital-based immunocompromised populations, where earlier recognition, laboratory capacity, and reliable antifungal access remain important to improving cryptococcosis outcomes.

China and India are central to long-term market expansion because of large patient bases, improving laboratory networks, broader hospital modernization, and increasing awareness of invasive fungal disease among HIV, oncology, and transplant populations. Japan, Australia, and South Korea have mature hospital systems and strong diagnostic adoption potential, supporting demand for high-quality CrAg testing, fungal culture, molecular tools, imaging-supported assessment, and safer antifungal regimens.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize access-oriented strategies that align diagnostics with treatment availability. Expanding CrAg screening without reliable antifungal supply limits clinical impact; therefore, coordinated portfolios that include rapid tests, confirmatory diagnostics, amphotericin B formulations, flucytosine, and fluconazole can create stronger public health value.

Manufacturers, distributors, and healthcare partners should invest in clinician education, laboratory quality assurance, cold-chain and stockout mitigation, pharmacovigilance, and evidence generation in high-burden settings. Partnerships with HIV programs, transplant centers, oncology networks, public laboratories, and global health agencies can accelerate adoption while supporting measurable reductions in cryptococcal meningitis mortality.

Research Methodology

This executive summary is developed using a structured secondary research approach grounded in publicly available guidance and surveillance from WHO, CDC, UNAIDS, national health agencies, peer-reviewed infectious disease literature, and clinical practice guidelines. The analysis emphasizes verified disease burden, diagnostic pathways, treatment recommendations, access constraints, and healthcare delivery realities.

Market interpretation combines epidemiological relevance, healthcare infrastructure assessment, product adoption dynamics, procurement patterns, regional policy context, and clinical pathway analysis. Insights are synthesized to support strategic decision-making across diagnostics, antifungal therapy, hospital care, HIV programs, transplant medicine, oncology care, and public health interventions without relying on unverified market-size claims.

Conclusion

The cryptococcosis market is defined by a clear clinical imperative: earlier detection and faster access to effective antifungal therapy can reduce deaths from cryptococcal meningitis. Diagnostic decentralization, treatment optimization, lumbar puncture capacity, and integration with HIV and immunocompromised care pathways remain the most important growth drivers.

Future competitiveness will depend on evidence-based product positioning, affordability, supply continuity, quality assurance, and partnerships that close gaps between screening and treatment. Organizations that combine clinical credibility with access-focused execution are best positioned to create durable impact in cryptococcosis care.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Cryptococcosis Market, by Drug Class
7.1. Introduction
7.2. Azoles
7.2.1. Fluconazole
7.2.2. Isavuconazole
7.2.3. Itraconazole
7.2.4. Posaconazole
7.2.5. Voriconazole
7.3. Echinocandins
7.3.1. Anidulafungin
7.3.2. Caspofungin
7.3.3. Micafungin
7.4. Polyenes
7.5. Pyrimidine Analogues
8. Cryptococcosis Market, by Indication
8.1. Introduction
8.2. Cryptococcal Meningitis
8.3. Disseminated Cryptococcosis
8.4. Pulmonary Cryptococcosis
9. Cryptococcosis Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous
9.3. Oral
10. Cryptococcosis Market, by End User
10.1. Introduction
10.2. Ambulatory Care Center
10.3. Clinic
10.4. Hospital
11. Cryptococcosis Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Cryptococcosis Market, by Region
12.1. Asia-Pacific
12.2. Europe
12.3. North America
12.4. Latin America
12.5. Africa
12.6. Middle East
13. Cryptococcosis Market, by Group
13.1. NATO
13.2. G7
13.3. BRICS
13.4. European Union
13.5. ASEAN
13.6. GCC
14. Cryptococcosis Market, by Country
14.1. China
14.2. United States
14.3. Japan
14.4. India
14.5. Germany
14.6. United Kingdom
14.7. Australia
14.8. France
14.9. South Korea
14.10. Italy
14.11. Canada
14.12. Russia
14.13. Brazil
14.14. Mexico
14.15. Spain
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Abbott Laboratories
16.2. Astellas Pharma Inc.
16.3. B.M. Pharmaceuticals
16.4. Bausch Health Companies Inc.
16.5. Bayer AG
16.6. Bristol-Myers Squibb Company
16.7. Citron Pharma
16.8. Eisai Co., Ltd.
16.9. Gilead Sciences, Inc.
16.10. GlaxoSmithKline PLC
16.11. Glenmark Pharmaceuticals Limited
16.12. Johnson & Johnson Services, Inc.
16.13. Jolly Limited
16.14. Lunan Pharmaceutical Group
16.15. Matinas Biopharma Holdings, Inc.
16.16. Merck & Co., Inc.
16.17. Novartis AG
16.18. NuCare Pharmaceuticals, Inc.
16.19. Pfizer Inc.
16.20. Sanofi S.A.
16.21. Sigmapharm Laboratories, LLC
16.22. Skyepharma Production SAS
16.23. Sumitomo Pharma Co., Ltd.
16.24. Takeda Pharmaceutical Company Limited
16.25. Teva Pharmaceutical Industries Ltd.
16.26. Viatris Inc.
List of Figures
FIGURE 1. GLOBAL CRYPTOCOCCOSIS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL CRYPTOCOCCOSIS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL CRYPTOCOCCOSIS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL CRYPTOCOCCOSIS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 7. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 13. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 15. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL CRYPTOCOCCOSIS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL CRYPTOCOCCOSIS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL CRYPTOCOCCOSIS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL AZOLES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL AZOLES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL AZOLES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL FLUCONAZOLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL FLUCONAZOLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL FLUCONAZOLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL ISAVUCONAZOLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL ISAVUCONAZOLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL ISAVUCONAZOLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL ITRACONAZOLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL ITRACONAZOLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL ITRACONAZOLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL POSACONAZOLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL POSACONAZOLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL POSACONAZOLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL VORICONAZOLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL VORICONAZOLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL VORICONAZOLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL ECHINOCANDINS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL ECHINOCANDINS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL ECHINOCANDINS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL ANIDULAFUNGIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL ANIDULAFUNGIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL ANIDULAFUNGIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL CASPOFUNGIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL CASPOFUNGIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL CASPOFUNGIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL MICAFUNGIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL MICAFUNGIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL MICAFUNGIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL POLYENES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL POLYENES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL POLYENES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL PYRIMIDINE ANALOGUES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL PYRIMIDINE ANALOGUES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL PYRIMIDINE ANALOGUES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL CRYPTOCOCCAL MENINGITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL CRYPTOCOCCAL MENINGITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL CRYPTOCOCCAL MENINGITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL DISSEMINATED CRYPTOCOCCOSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL DISSEMINATED CRYPTOCOCCOSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL DISSEMINATED CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL PULMONARY CRYPTOCOCCOSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL PULMONARY CRYPTOCOCCOSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL PULMONARY CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL AMBULATORY CARE CENTER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL AMBULATORY CARE CENTER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL AMBULATORY CARE CENTER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL CLINIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL CLINIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL CLINIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL HOSPITAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL HOSPITAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL HOSPITAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 79. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 80. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 81. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2017-2032 (USD MILLION)
TABLE 82. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 83. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 84. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 85. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 86. EUROPE CRYPTOCOCCOSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. EUROPE CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 88. EUROPE CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 89. EUROPE CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2017-2032 (USD MILLION)
TABLE 90. EUROPE CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 91. EUROPE CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 92. EUROPE CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 93. EUROPE CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 94. NORTH AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 95. NORTH AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 96. NORTH AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 97. NORTH AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2017-2032 (USD MILLION)
TABLE 98. NORTH AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 99. NORTH AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 100. NORTH AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 101. NORTH AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 102. LATIN AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 103. LATIN AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 104. LATIN AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 105. LATIN AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2017-2032 (USD MILLION)
TABLE 106. LATIN AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 107. LATIN AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 108. LATIN AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 109. LATIN AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 110. AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 111. AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 112. AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 113. AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2017-2032 (USD MILLION)
TABLE 114. AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 115. AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 116. AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 117. AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 118. MIDDLE EAST CRYPTOCOCCOSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 119. MIDDLE EAST CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 120. MIDDLE EAST CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 121. MIDDLE EAST CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2017-2032 (USD MILLION)
TABLE 122. MIDDLE EAST CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 123. MIDDLE EAST CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 124. MIDDLE EAST CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 125. MIDDLE EAST CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 127. NATO CRYPTOCOCCOSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 128. NATO CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 129. NATO CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 130. NATO CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2017-2032 (USD MILLION)
TABLE 131. NATO CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 132. NATO CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 133. NATO CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 134. NATO CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 135. G7 CRYPTOCOCCOSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 136. G7 CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 137. G7 CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 138. G7 CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2017-2032 (USD MILLION)
TABLE 139. G7 CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 140. G7 CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 141. G7 CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 142. G7 CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 143. BRICS CRYPTOCOCCOSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 144. BRICS CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 145. BRICS CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 146. BRICS CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2017-2032 (USD MILLION)
TABLE 147. BRICS CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 148. BRICS CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 149. BRICS CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 150. BRICS CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 151. EUROPEAN UNION CRYPTOCOCCOSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 152. EUROPEAN UNION CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 153. EUROPEAN UNION CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 154. EUROPEAN UNION CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2017-2032 (USD MILLION)
TABLE 155. EUROPEAN UNION CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 156. EUROPEAN UNION CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 157. EUROPEAN UNION CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 158. EUROPEAN UNION CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 159. ASEAN CRYPTOCOCCOSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 160. ASEAN CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 161. ASEAN CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 162. ASEAN CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2017-2032 (USD MILLION)
TABLE 163. ASEAN CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 164. ASEAN CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 165. ASEAN CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 166. ASEAN CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 167. GCC CRYPTOCOCCOSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 168. GCC CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 169. GCC CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 170. GCC CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2017-2032 (USD MILLION)
TABLE 171. GCC CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 172. GCC CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 173. GCC CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 174. GCC CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 175. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 176. CHINA CRYPTOCOCCOSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 177. CHINA CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 178. CHINA CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 179. CHINA CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2017-2032 (USD MILLION)
TABLE 180. CHINA CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 181. CHINA CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 182. CHINA CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 183. CHINA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 184. UNITED STATES CRYPTOCOCCOSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 185. UNITED STATES CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 186. UNITED STATES CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 187. UNITED STATES CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2017-2032 (USD MILLION)
TABLE 188. UNITED STATES CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 189. UNITED STATES CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 190. UNITED STATES CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 191. UNITED STATES CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 192. JAPAN CRYPTOCOCCOSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 193. JAPAN CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 194. JAPAN CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 195. JAPAN CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2017-2032 (USD MILLION)
TABLE 196. JAPAN CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 197. JAPAN CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 198. JAPAN CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 199. JAPAN CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 200. INDIA CRYPTOCOCCOSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 201. INDIA CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 202. INDIA CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 203. INDIA CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2017-2032 (USD MILLION)
TABLE 204. INDIA CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 205. INDIA CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 206. INDIA CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 207. INDIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 208. GERMANY CRYPTOCOCCOSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 209. GERMANY CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 210. GERMANY CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 211. GERMANY CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2017-2032 (USD MILLION)
TABLE 212. GERMANY CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 213. GERMANY CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 214. GERMANY CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 215. GERMANY CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 216. UNITED KINGDOM CRYPTOCOCCOSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 217. UNITED KINGDOM CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 218. UNITED KINGDOM CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 219. UNITED KINGDOM CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2017-2032 (USD MILLION)
TABLE 220. UNITED KINGDOM CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 221. UNITED KINGDOM CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 222. UNITED KINGDOM CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 223. UNITED KINGDOM CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 224. AUSTRALIA CRYPTOCOCCOSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 225. AUSTRALIA CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 226. AUSTRALIA CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 227. AUSTRALIA CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2017-2032 (USD MILLION)
TABLE 228. AUSTRALIA CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 229. AUSTRALIA CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 230. AUSTRALIA CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 231. AUSTRALIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 232. FRANCE CRYPTOCOCCOSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 233. FRANCE CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 234. FRANCE CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 235. FRANCE CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2017-2032 (USD MILLION)
TABLE 236. FRANCE CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 237. FRANCE CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 238. FRANCE CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 239. FRANCE CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 240. SOUTH KOREA CRYPTOCOCCOSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 241. SOUTH KOREA CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 242. SOUTH KOREA CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 243. SOUTH KOREA CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2017-2032 (USD MILLION)
TABLE 244. SOUTH KOREA CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 245. SOUTH KOREA CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 246. SOUTH KOREA CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 247. SOUTH KOREA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 248. ITALY CRYPTOCOCCOSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 249. ITALY CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 250. ITALY CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 251. ITALY CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2017-2032 (USD MILLION)
TABLE 252. ITALY CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 253. ITALY CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 254. ITALY CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 255. ITALY CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 256. CANADA CRYPTOCOCCOSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 257. CANADA CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 258. CANADA CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 259. CANADA CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2017-2032 (USD MILLION)
TABLE 260. CANADA CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 261. CANADA CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 262. CANADA CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 263. CANADA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 264. RUSSIA CRYPTOCOCCOSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 265. RUSSIA CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 266. RUSSIA CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 267. RUSSIA CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2017-2032 (USD MILLION)
TABLE 268. RUSSIA CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 269. RUSSIA CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 270. RUSSIA CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 271. RUSSIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 272. BRAZIL CRYPTOCOCCOSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 273. BRAZIL CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 274. BRAZIL CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 275. BRAZIL CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2017-2032 (USD MILLION)
TABLE 276. BRAZIL CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 277. BRAZIL CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 278. BRAZIL CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 279. BRAZIL CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 280. MEXICO CRYPTOCOCCOSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 281. MEXICO CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 282. MEXICO CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 283. MEXICO CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2017-2032 (USD MILLION)
TABLE 284. MEXICO CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 285. MEXICO CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 286. MEXICO CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 287. MEXICO CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 288. SPAIN CRYPTOCOCCOSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 289. SPAIN CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 290. SPAIN CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 291. SPAIN CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2017-2032 (USD MILLION)
TABLE 292. SPAIN CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 293. SPAIN CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 294. SPAIN CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 295. SPAIN CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 296. GLOBAL CRYPTOCOCCOSIS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 297. GLOBAL CRYPTOCOCCOSIS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

  • Abbott Laboratories
  • Astellas Pharma Inc.
  • B.M. Pharmaceuticals
  • Bausch Health Companies Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Citron Pharma
  • Eisai Co., Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Johnson & Johnson Services, Inc.
  • Jolly Limited
  • Lunan Pharmaceutical Group
  • Matinas Biopharma Holdings, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • NuCare Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Sigmapharm Laboratories, LLC
  • Skyepharma Production SAS
  • Sumitomo Pharma Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

Table Information

Report AttributeDetails
No. of Pages182
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 7.18 Billion
Forecasted Market Value ( USD ) by 2032 $ 9.49 Billion
Compound Annual Growth Rate4.7%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Cryptococcosis Treatment Market - Global Forecast 2026-2032 - Product Image

Cryptococcosis Treatment Market - Global Forecast 2026-2032

  • Report
  • 188 Pages
  • Global
From
Cryptococcosis Therapeutics - Global Strategic Business Report - Product Image

Cryptococcosis Therapeutics - Global Strategic Business Report

  • Report
  • 473 Pages
  • Global
From
Cryptococcosis Drugs Market Outlook 2026-2036 - Product Image

Cryptococcosis Drugs Market Outlook 2026-2036

  • Report
  • 299 Pages
  • Global
From
Cryptococcosis Therapeutics Market Report 2026 - Product Image

Cryptococcosis Therapeutics Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Cryptococcosis Treatment - Global Strategic Business Report - Product Image

Cryptococcosis Treatment - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.